Arrowhead Pharmaceuticals, Inc. today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due 2032 (the "notes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback